Stock Financial Ratios


PTI / Proteostasis Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.16
Volume379,700.00
Market Cap ($M)39.39
Enterprise Value ($M)15.47
Book Value ($M)81.46
Book Value / Share4.34
Price / Book2.78
NCAV ($M)82.39
NCAV / Share4.39
Price / NCAV4.34
Income Statement (mra) ($M)
Revenue8.38
EBITDA-37.45
Net Income-37.23
Balance Sheet (mrq) ($M)
Cash & Equivalents18.19
Cash / Share0.97
Assets60.72
Liabilities22.40
Quick Ratio10.31
Current Ratio10.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.46
Return on Assets (ROA)-0.41
Return on Equity (ROE)-0.46
Identifiers and Descriptors
CUSIP74373B109
Central Index Key (CIK)1445283
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)25.22
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Property Plant And Equipment Net Per Share0.67
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Debt Per Share0.00
Assets Current Per Share2.48
Deferred Income Tax Liabilities Per Share0.00
Liabilities Other Non Current Per Share0.61
Retained Earnings Per Share-10.85
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Assets Per Share3.24
Cash And Equivalents Per Share0.97
Intangibles Per Share0.00
Cash Per Share0.97
Property Plant And Equipment Per Share0.67
Additional Paid In Capital Per Share12.89
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Per Share1.19
Liabilities And Stock Equity Per Share3.24
Accounts Receivable Per Share0.06
Minority Interest Per Share0.00
Liabilities Current Per Share0.59
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Equity Per Share2.04
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00

Related News Stories

Proteostasis Therapeutics Inc (PTI) Short Interest Down 52.3% in December - The Lincolnian Online

2018-01-16 thelincolnianonline
Proteostasis Therapeutics Inc (NASDAQ:PTI) was the recipient of a significant decline in short interest during the month of December. As of December 29th, there was short interest totalling 919,447 shares, a decline of 52.3% from the December 15th total of 1,927,302 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 1,134,827 shares, the short-interest ratio is currently 0. (16-0)

Proteostasis Therapeutics: A 'Deep Dive' On This ~$6 Busted IPO

2018-01-06 seekingalpha
We take a look at the company's pipeline, upcoming catalysts, review recent analyst commentary and render a verdict on the stock below. (16-0)

Weekly Insider Trading

2017-12-28 seekingalpha
It is Christmas time and some extra time to... work! My pilot article ("Weekly Insider Trading") was published as recently as December 23, but it covered four biotech and IT companies with the most interesting insider trading dating back 3 months. This article follows my standard work and investing process by looking back at the last week’s most interesting transactions. (291-2)

Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement

2017-12-15 seekingalpha
Today we will discuss an article on Conatus Pharmaceuticals (CNAT) by Stephen Ayers, titled, “Conatus: Likely To Dash Ahead Of NASH Data.” (163-6)

Proteostasis Stock Surges on Positive Data From CF Studies

2017-12-13 zacks
Proteostasis Therapeutics, Inc.’s (PTI - Free Report) shares surged more than 160% on Dec 12 after the announcement of positive results from studies evaluating its three cystic fibrosis ("CF") pipeline candidates. The three candidates include PTI-428 (a cystic fibrosis transmembrane conductance regulator [CFTR] amplifier), PTI-801 (a CFTR corrector) and PTI-808 (a CFTR potentiator). (79-3)

CUSIP: 74373B109